Expression of USP22 in Patients with Acute Leukemia and Its Clinical Signifi cance
-
摘要: 目的 探讨特异性泛素蛋白酶22（USP22）在急性白血病（AL）细胞中的表达及其临床意义。方法 采用荧光定量PCR及Western blot检测USP22基因及蛋白在Jurkat、HL-60、K562、molt-4和NB4细胞系、急性白血病患者及阴性对照者骨髓单个核细胞中的表达量情况。结果 USP22在Jurkat、HL-60、K562、molt-4和NB4细胞系均有所表达。USP22 mRNA在急性白血病患者初诊组（33.90±9.58）、缓解组（1.81±0.53）中的表达量与阴性对照组（1.05±0.33）相比均上调，USP22蛋白在急性白血病患者初诊组（0.58±0.15）、缓解组（0.10±0.03）中的表达量与阴性对照组（0.05±0.02）相比均上调，差异均具有统计学意义（P<0.001）；其中USP22 mRNA在初诊组高白细胞AL患者中的表达量（45.23±10.92）高于非高白细胞患者（26.73±6.12），USP22蛋白在初诊组高白细胞急性白血病患者中的表达量（0.69±0.16）高于非高白细胞患者（0.42±0.10），差异均具有统计学意义（P＜0.001）。但USP22基因和蛋白在初诊组急性髓系白血病（AML）与急性淋巴细胞白血病（ALL）患者间的表达差异无统计学意义（P=0.531, 0.377），并且本研究对急性白血病患者的临床转归进行了观察，与低表达USP22的急性白血病患者初次诱导缓解率（88.0%）相比，高表达的缓解率（54.17%）较低。结论 USP22在急性白血病中表达率较高，它的表达水平可能与白细胞数目有关，USP22可作为判断急性白血病患者预后的标志基因之一。
-
关键词:
- 特异性泛素蛋白酶22 /
- 急性白血病 /
- 肿瘤干细胞 /
- 预后
Abstract: Objective To investigate the expression of ubiquitin-specifi c protease 22(USP22) in bone marrow cells in patients with acute leukemia(AL) and its clinical signifi cance. Methods Real-time quantitative PCR (qPCR) and Western blot were used to detect mRNA and protein expression levels of USP22 in Jurkat, HL-60, K562, molt-4 and NB4 cell lines and bone marrow mononuclear cells from AL patients and negative control patients, respectively. Results USP22 expression was found in Jurkat, HL-60, K562, molt-4 and NB4 cell lines. mRNA and protein expressions of USP22 in initial diagnosis group (33.90±9.58) and (0.58±0.15) and remission group(1.81±0.53) and (0.10±0.03) were both increased, compared with that in negative control group (1.05±0.33) and (0.05±0.02) (P<0.001). Meanwhile, expression levels of USP22 mRNA and protein in hyperleukocytic AL patients in initial diagnosis group (45.23±10.92) and (0.69±0.16) were significantly higher than those in non-hyperleukocytic AL patients [(26.73±6.12) and (0.42±0.10), P<0.001]. But no signifi cant difference of USP22 and protein expressions was found between acute myeloid leukemia(AML) and acute lymphoblastic leukemia (ALL) patients in initial diagnosis group (P=0.531, 0.377). Moreover, AL patients with higher USP22 expression (54.17%) had lower complete remission rate than that with lower USP22 expression (88.0%) after the fi rst induction chemotherapy. Conclusion USP22 is highly expressed in AL patients and decreased after complete remission, which might relate to leukocytes number. Taken together, it could be a useful parameter for prognosis of AL patients.-
Key words:
- USP22 /
- Acute leukemia /
- Tumor stem cell /
- Prognosis
-
-
[1] Lee HJ, Kim MS, Shin JM, et al. The expression patterns of deubiquitinating enzymes, USP22 and Usp22[J]. Gene Expr Patterns, 2006, 6(3): 277-84. [2] Zhang XY, Varthi M, Sykes SM, et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression[J]. Mol Cell, 2008, 29(1): 102-11. [3] Glinsky GV. Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway[J]. Cell Cycle, 2006, 5(11): 1208-16. [4] Zhang Y,Yao L,Zhang X,et al. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer[J]. J Cancer Res Clin Oncol, 2011, 137(8):1245-53. [5] Hu J, Liu YL, Piao SL, et al. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer[J]. Lung Cancer, 2012, 77(3): 593-9. [6] Yang DD, Cui BB, Sun LY, et al. The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma[J]. Cell Biochem Biophys, 20 11,61(3): 703-10. [7] Zhou F,Cui BB,Liu YL,et al. Expression and clinical signifi cance of usp22 and ki67 in colorectal carcinoma[J].Zhong Liu Fang Zhi Yan Jiu ,2012,39(1):68-70.[ 周飞,崔滨滨,刘彦龙,等.USP22 和ki67在大肠癌组织中的表达及其临床意义[J].肿瘤防治研 究,2012,39(1):68-70.] [8] Zhang ZN,Shen T. Haematology diagnostic and curative standard[M].Beijing:Science Press,2009: 103-34.[张之南, 沈 悌. 血液病诊断及疗效标准[M].北京:科学出版社, 2009: 103-34.] [9] Ao N,Liu YQ.Research advances in the function of USP22 in the occurrence and development of tumor[J].Ji Chu Yi Xue Yu Lin Chuang,2012, 32(10): 1235-8.[ 敖宁,刘玉琴. USP22在肿瘤发 生发展中的作用研究进展[J]. 基础医学与临床, 2012,32(10): 12 35-8.] [10] Liu Y,Yang Y,Xu H, et al. Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas[J]. Diagn Mol Pathol, 2010, 19 (4): 194-200. [11] Liu YL, Jiang SX, Yang YM, et al. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway[J]. Cell Biochem Biophys, 2012,62(1): 229-35. [12] Song LB, Li J, Liao WT, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelialmesenchymal transition in human nasopharyngeal epithelial cells[J]. J Clin Invest, 2009,119(12): 3626-36.
计量
- 文章访问数: 1904
- HTML全文浏览量: 447
- PDF下载量: 819
下载:
